샘플 요청 목록

 카트 문의
시장보고서
상품코드
1791915

세계의 마이크로바이옴 진단 시장

Microbiome Diagnostics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 569 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 마이크로바이옴 진단 시장은 2030년까지 3억 3,410만 달러에 달할 전망

2024년에 1억 5,740만 달러로 추정되는 세계의 마이크로바이옴 진단 시장은 2030년에는 3억 3,410만 달러에 달할 것으로 예측되며, 분석 기간 2024-2030년 CAGR은 13.4%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 마이크로바이옴 진단 키트 & 시약은 CAGR 15.3%를 기록하며, 분석 기간 종료까지 2억 2,990만 달러에 달할 것으로 예측됩니다. 마이크로바이옴 진단 기기 부문의 성장률은 분석 기간에 CAGR 9.8%로 추정됩니다.

미국 시장은 4,290만 달러로 추정, 중국은 CAGR 18.2%로 성장 예측

미국의 마이크로바이옴 진단 시장은 2024년에는 4,290만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년에 CAGR 18.2%로 추이하며, 2030년에는 7,210만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 9.6%와 12.0%로 예측됩니다. 유럽에서는 독일이 CAGR 10.6%로 성장할 것으로 예측됩니다.

세계의 마이크로바이옴 진단 시장 - 주요 동향과 촉진요인 정리

마이크로바이옴 진단이란 무엇이며, 헬스케어에 어떤 영향을 미치는가?

마이크로바이옴 진단이란 인체 내, 주로 장내에 서식하는 수조 개의 미생물(박테리아, 곰팡이, 바이러스, 고세균)로 구성된 인간 마이크로바이옴을 검사하고 분석하는 것을 말합니다. 이러한 미생물은 면역기능과 신진대사, 나아가 정신건강까지 영향을 미치며 건강 전반에 걸쳐 중요한 역할을 합니다. 마이크로바이옴 진단은 종종 첨단 시퀀싱 기술과 생물정보학을 통해 이러한 미생물 군집의 동정, 특성 분석 및 모니터링을 수행합니다. 이러한 진단을 통해 얻어진 지식은 개인의 마이크로바이옴 구성에 기반한 헬스케어에 대한 보다 타겟화된 접근 방식을 제공하여 맞춤형 의료를 변화시킬 수 있는 잠재력을 가지고 있습니다.

마이크로바이옴 진단은 일반적으로 16S rRNA 유전자 시퀀싱, 메타유전체 시퀀싱, 샷건 시퀀싱 등의 기술을 사용하여 미생물의 다양성을 매핑하고 환자에게 존재하는 특정 미생물 종을 식별합니다. 마이크로바이옴의 구성을 이해함으로써 연구자와 의료진은 위장 장애, 자가면역 질환, 비만, 당뇨병, 우울증, 불안증과 같은 신경증상 등 다양한 건강 상태와 관련된 불균형과 불균형을 파악할 수 있습니다. 미생물 균형을 회복시킴으로써 이러한 증상을 치료하거나 관리할 수 있으므로 마이크로바이옴 진단에 대한 관심과 투자가 증가하고 있습니다.

마이크로바이옴 진단은 질병 진행 모니터링, 치료 효과 판단, 질병 위험 예측에도 적용될 수 있습니다. 연구자들이 마이크로바이옴과 건강 사이의 복잡한 관계를 계속 탐구함에 따라 진단 툴은 임상의가 다양한 질병의 바이오마커를 식별하고, 조기 발견을 개선하고, 정밀의료를 촉진할 수 있게 해줍니다. 이처럼 마이크로바이옴 진단은 헬스케어의 패러다임 전환을 상징하며, 질병 관리와 예방에 대한 보다 총체적이고 개별화된 접근 방식을 제공합니다.

마이크로바이옴 진단 시장을 형성하는 주요 동향은?

마이크로바이옴 진단 시장에 영향을 미치는 주요 동향은 맞춤형 의료와 정밀의료의 중요성이 높아지고 있다는 점입니다. 기존의 진단법은 일반화된 경우가 많아 미생물 군집의 개인차를 고려하지 않은 경우가 많습니다. 반면, 마이크로바이옴 진단은 암, 당뇨병, 과민성 대장 증후군(IBS) 등의 질병 위험에 영향을 미칠 수 있는 미생물 불균형을 파악하여 개인의 건강 상태를 고도로 개별화할 수 있습니다. 정밀의료가 대중화됨에 따라 미생물 진단은 각 환자의 고유한 미생물학적 프로파일에 맞는 치료법을 제공하는 데 필수적인 역할을 할 것으로 기대되고 있습니다.

또 다른 중요한 동향은 프로바이오틱스, 프리바이오틱스, 마이크로바이옴 이식 등 마이크로바이옴 기반 치료제의 이용이 증가하고 있다는 점입니다. 이러한 치료법은 체내의 건강한 미생물 균형을 회복하는 것을 목표로 하며, 위장 문제부터 정신 질환에 이르기까지 다양한 증상의 치료가 가능하다는 점에서 많은 지지를 받고 있습니다. 마이크로바이옴이 인체 건강에 필수적인 요소로 인식되면서 미생물 불균형을 식별하는 진단 툴은 가장 적절한 치료 개입을 결정하는 데 필수적인 툴이 되고 있습니다. 마이크로바이옴 기반 치료법 개발은 마이크로바이옴 진단의 발전과 밀접한 관련이 있으며, 이러한 기술은 마이크로바이옴 의료 분야에서 일하는 연구자와 임상의사 모두에게 필수적인 기술입니다.

마이크로바이옴 진단에 인공지능(AI)과 머신러닝(ML)을 통합하는 것도 중요한 동향입니다. AI와 ML 기술은 매우 복잡하고 다차원적일 수 있는 복잡한 마이크로바이옴 데이터를 분석할 수 있게 해줍니다. 이러한 첨단 기술은 미생물 구성과 건강 결과의 숨겨진 패턴과 상관관계를 파악하여 마이크로바이옴 진단의 정확성과 예측력을 향상시킵니다. AI 기반 알고리즘은 임상시험에서 얻은 대규모 데이터세트 분석에도 사용되어 미생물 군집이 질병의 진행과 치료 반응에 미치는 영향에 대한 귀중한 인사이트를 제공합니다. 그 결과, AI와 ML은 마이크로바이옴 진단의 기능과 응용을 발전시키는 데 있으며, 점점 더 중요한 역할을 할 것으로 예측됩니다.

마이크로바이옴 진단이 헬스케어와 질병 관리에 어떻게 도움이 되는가?

마이크로바이옴 진단은 보다 정확한 질병 발견, 맞춤형 치료 계획, 더 나은 환자 결과를 가능하게 함으로써 의료를 변화시키고 있습니다. 가장 두드러진 용도 중 하나는 소화기 질환입니다. IBS, 크론병, 궤양성 대장염 등의 질환은 장내 미생물의 불균형과 밀접한 관련이 있지만, 기존의 진단 방법으로는 근본적인 미생물의 원인을 파악할 수 없는 경우가 많습니다. 마이크로바이옴 진단은 장내세균총의 구성을 분석함으로써 이러한 질병에 대한 보다 명확한 이해를 제공하고, 이러한 질병을 보다 정확하게 진단하고 그 진행을 모니터링하는 데 도움이 될 수 있습니다.

소화기 질환 외에도 비만, 2형 당뇨병, 심혈관 질환 등 대사성 질환에 대한 마이크로바이옴 진단도 유망합니다. 연구에 따르면 장내세균총은 신진대사, 인슐린 감수성, 지방 축적 조절에 중요한 역할을 하는 것으로 나타났습니다. 대사 상태와 관련된 특정 미생물 종과 미생물 패턴을 식별함으로써, 미생물 진단은 조기 발견을 돕고, 식이 및 의약품 개입의 효과를 모니터링하는 데 도움이 됩니다. 또한 마이크로바이옴 진단은 만성질환의 미생물 바이오마커를 식별하여 임상의가 질병의 진행을 추적하고 그에 따라 치료를 맞춤화할 수 있게 해줍니다.

마이크로바이옴 진단은 암 치료의 가능성도 연구되고 있습니다. 최근 연구에 따르면 마이크로바이옴이 화학요법, 면역요법 등 암 치료의 효과에 영향을 미칠 수 있다는 가능성이 제시되고 있습니다. 예를 들어 특정 장내세균총은 암 치료에서 면역관문억제제의 효과를 높이는 것으로 밝혀졌습니다. 마이크로바이옴 진단은 암 환자의 특정 미생물 구성을 파악하여 어떤 환자가 특정 치료에 반응하기 쉬운지 예측하고 치료 결과를 개선하는 데 도움이 될 수 있습니다. 이 접근법은 궁극적으로 보다 표적화된 암 치료와 환자의 생존율 향상으로 이어질 수 있습니다.

마이크로바이옴 진단 시장의 주요 성장 촉진요인은?

마이크로바이옴 진단 시장의 성장은 만성질환의 유병률 증가, 유전체 시퀀싱 기술의 발전, 개인 맞춤형 헬스케어에 대한 관심 증가 등 여러 요인에 의해 이루어지고 있습니다. 비만, 당뇨병, 위장병 등 만성질환은 전 세계에서 지속적으로 증가하고 있으며, 그 근본적인 원인에 대한 더 깊은 인사이트를 제공할 수 있는 진단 툴에 대한 요구가 증가하고 있습니다. 마이크로바이옴 진단은 이러한 질병의 발병과 진행에 관여하는 미생물의 불균형을 보다 정확하게 감지하여 조기 개입과 효과적인 관리로 이어지게 함으로써 이러한 요구에 부응하는 것입니다.

유전체 시퀀싱 기술의 발전도 주요 촉진요인입니다. 차세대 염기서열 분석(NGS)과 같은 하이스루풋 시퀀싱 기술의 발달로 미생물 유전체 염기서열 분석에 필요한 비용과 시간이 크게 줄어들어 마이크로바이옴 분석이 보다 친숙하고 비용 효율적으로 이루어지고 있습니다. 시퀀싱 기술이 발전함에 따라 마이크로바이옴 진단은 더욱 정확하고 다양한 미생물 종을 식별할 수 있게 되었습니다. 이를 통해 환자의 건강 상태에 대한 실질적인 정보를 얻기 위해 임상 현장에서 사용할 수 있는 보다 종합적인 진단 검사를 개발할 수 있게 되었습니다.

맞춤형 의료가 강조되고 있는 것도 시장을 촉진하는 큰 요인이 되고 있습니다. 헬스케어가 유전적, 환경적, 생활습관적 요인에 기반한 개인 맞춤형 치료 계획으로 전환되고 있는 가운데, 마이크로바이옴 진단은 보다 개인화된 헬스케어 솔루션을 제공하는 데 있으며, 중요한 역할을 하고 있습니다. 환자의 마이크로바이옴에 대한 상세한 분석을 제공함으로써 의료 서비스 프로바이더는 환자별 미생물 프로파일에 더 적합한 맞춤형 치료 요법을 개발할 수 있습니다. 이 접근법은 개인 맞춤형 치료가 환자의 예후 개선에 필수적인 종양학 등의 분야에서 특히 유용합니다.

또한 마이크로바이옴 연구에 대한 투자가 증가하면서 새로운 진단 툴와 치료제 개발이 가속화되고 있습니다. 정부기관, 비상장기업, 연구기관들이 마이크로바이옴 연구에 많은 투자를 하고 있으며, 다양한 질병 치료에 대한 가능성을 모색하고 있습니다. 이러한 연구의 급증은 새로운 바이오마커의 발견과 새로운 진단 플랫폼의 개발로 이어져 마이크로바이옴 진단 시장의 성장을 더욱 촉진하고 있습니다. 인체 건강에서 마이크로바이옴의 중요성이 인식되면서 시장은 빠르게 성장하고 있으며, 진단 기업, 의료 서비스 프로바이더 및 환자에게 새로운 기회를 제공할 것으로 예측됩니다.

결론적으로 마이크로바이옴 진단 시장은 시퀀싱 기술의 발전, 맞춤형 의료의 부상, 정밀한 질병 관리 툴에 대한 수요 증가로 인해 강력한 성장세를 보이고 있습니다. 마이크로바이옴에 대한 이해가 깊어지고 인간 건강에서 마이크로바이옴의 역할이 인식됨에 따라 마이크로바이옴 진단은 헬스케어의 초석이 될 준비가 되어 있습니다. 마이크로바이옴을 분석하고 조작하는 능력은 질병 발견을 개선할 뿐만 아니라, 새로운 치료법과 보다 효과적인 예방 전략의 길을 열어 세계 산업 분석가들이 알고 있는 헬스케어에 변화를 가져올 것입니다.

부문

제품 유형(마이크로바이옴 진단 키트·시약, 마이크로바이옴 진단 기기), 기술(16S rRNA 시퀀스 기술, 샷건·군유전체학 기술, Metatranscriptomics 기술, 기타 기술), 샘플 유형(분변 샘플, 타액 샘플, 피부 샘플, 기타 샘플 유형), 용도(질환 진단 용도, 연구 용도), 최종 용도(병원 최종 용도, 학술·연구기관 최종 용도, 제약·바이오 기업 최종 용도)

조사 대상 기업의 예

  • Alba Health
  • Axial Biotherapeutics
  • Beo Therapeutics
  • BioMed Technology Holdings
  • bioMerieux
  • Daye
  • Evelo Biosciences
  • Extension Health
  • Function Health
  • Microba
  • Nexilico
  • Ombre
  • Pendulum Therapeutics
  • Rebiotix Inc.
  • Seres Therapeutics
  • Siolta Therapeutics
  • Sun Genomics
  • Vedanta Biosciences
  • Viavi

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA

Global Microbiome Diagnostics Market to Reach US$334.1 Million by 2030

The global market for Microbiome Diagnostics estimated at US$157.4 Million in the year 2024, is expected to reach US$334.1 Million by 2030, growing at a CAGR of 13.4% over the analysis period 2024-2030. Microbiome Diagnostic Kits & Reagents, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$229.9 Million by the end of the analysis period. Growth in the Microbiome Diagnostic Instruments segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.9 Million While China is Forecast to Grow at 18.2% CAGR

The Microbiome Diagnostics market in the U.S. is estimated at US$42.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$72.1 Million by the year 2030 trailing a CAGR of 18.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Microbiome Diagnostics Market - Key Trends & Drivers Summarized

What Are Microbiome Diagnostics and How Do They Impact Healthcare?

Microbiome diagnostics refer to the testing and analysis of the human microbiome, which comprises the trillions of microorganisms (bacteria, fungi, viruses, and archaea) that live in and on the human body, primarily in the gut. These microorganisms play a crucial role in maintaining overall health, influencing immune function, metabolism, and even mental health. Microbiome diagnostics involve identifying, characterizing, and monitoring these microbial communities, often through advanced sequencing technologies and bioinformatics. The insights derived from these diagnostics have the potential to transform personalized medicine, offering a more targeted approach to healthcare based on an individual’s microbiome composition.

Microbiome diagnostics typically employ techniques like 16S rRNA gene sequencing, metagenomic sequencing, and shotgun sequencing to map out microbial diversity and identify specific microbial species present in a patient. By understanding the composition of the microbiome, researchers and healthcare providers can identify imbalances or dysbiosis, which is associated with a range of health conditions, including gastrointestinal disorders, autoimmune diseases, obesity, diabetes, and even neurological conditions like depression and anxiety. The potential to treat or manage these conditions by restoring microbial balance is driving the growing interest and investment in microbiome diagnostics.

Microbiome diagnostics also have applications in monitoring disease progression, determining the effectiveness of treatments, and predicting disease risk. As researchers continue to explore the complex relationship between the microbiome and health, diagnostics tools will enable clinicians to identify biomarkers for various diseases, improving early detection and facilitating precision medicine. As such, microbiome diagnostics represent a paradigm shift in healthcare, offering a more holistic and personalized approach to disease management and prevention.

What Are the Key Trends Shaping the Microbiome Diagnostics Market?

A major trend influencing the microbiome diagnostics market is the growing emphasis on personalized and precision medicine. Traditional diagnostic methods are often generalized and may not account for individual differences in microbial communities. In contrast, microbiome diagnostics allow for highly personalized insights into a person’s health, identifying microbial imbalances that could influence their risk of diseases such as cancer, diabetes, and irritable bowel syndrome (IBS). As precision medicine becomes more prevalent, microbiome diagnostics are expected to play an integral role in tailoring therapies to the unique microbiological profile of each patient.

Another important trend is the increasing use of microbiome-based therapeutics, such as probiotics, prebiotics, and microbiome transplants. These therapies aim to restore a healthy microbial balance in the body and are gaining traction due to their potential to treat a variety of conditions, from gastrointestinal issues to mental health disorders. As the microbiome is increasingly recognized as an integral part of human health, diagnostics tools that help identify microbial imbalances are becoming critical for determining the most appropriate therapeutic interventions. The development of microbiome-based therapeutics is closely tied to advances in microbiome diagnostics, making these technologies essential for both researchers and clinicians working in the field of microbiome medicine.

The integration of artificial intelligence (AI) and machine learning (ML) in microbiome diagnostics is another key trend. AI and ML technologies are enabling the analysis of complex microbiome data, which can be highly intricate and multidimensional. These advanced technologies can identify hidden patterns and correlations between microbial composition and health outcomes, improving the accuracy and predictive power of microbiome diagnostics. AI-powered algorithms are also being used to analyze large datasets from clinical trials, providing valuable insights into how microbial communities influence disease progression and treatment response. As a result, AI and ML are expected to play an increasingly important role in advancing the capabilities and applications of microbiome diagnostics.

How Are Microbiome Diagnostics Benefiting Healthcare and Disease Management?

Microbiome diagnostics are transforming healthcare by enabling more accurate disease detection, personalized treatment plans, and better patient outcomes. One of the most prominent applications is in gastrointestinal disorders. Conditions like IBS, Crohn’s disease, and ulcerative colitis are strongly linked to microbial imbalances in the gut, and traditional diagnostic methods often fail to identify the underlying microbial causes. Microbiome diagnostics can provide a clearer understanding of these disorders by analyzing gut microbiota composition, which can help in diagnosing these conditions more accurately and monitoring their progression.

In addition to gastrointestinal conditions, microbiome diagnostics have shown promise in addressing metabolic diseases like obesity, type 2 diabetes, and cardiovascular disease. Research has shown that the gut microbiome plays a significant role in regulating metabolism, insulin sensitivity, and fat storage. By identifying specific microbial species or microbial patterns associated with metabolic conditions, microbiome diagnostics can assist in early detection and help monitor the effectiveness of dietary or pharmaceutical interventions. Furthermore, microbiome diagnostics can identify microbial biomarkers for chronic diseases, enabling clinicians to track disease progression and customize treatments accordingly.

Microbiome diagnostics are also being explored for their potential in cancer treatment. Recent studies suggest that the microbiome may influence the efficacy of cancer therapies, including chemotherapy and immunotherapy. For example, certain gut microbiota have been found to enhance the effectiveness of immune checkpoint inhibitors in cancer treatment. By identifying specific microbial compositions in cancer patients, microbiome diagnostics may help predict which patients are more likely to respond to certain treatments, thereby improving treatment outcomes. This approach could ultimately lead to more targeted cancer therapies and better survival rates for patients.

What Are the Key Growth Drivers in the Microbiome Diagnostics Market?

The growth in the microbiome diagnostics market is driven by several factors, including the increasing prevalence of chronic diseases, advancements in genomic sequencing technologies, and the growing focus on personalized healthcare. As chronic diseases such as obesity, diabetes, and gastrointestinal disorders continue to rise worldwide, there is a growing need for diagnostic tools that can offer deeper insights into their underlying causes. Microbiome diagnostics address this need by enabling more precise detection of microbial imbalances that contribute to the onset and progression of these diseases, leading to earlier intervention and more effective management.

Advancements in genomic sequencing technologies are another major growth driver. The development of high-throughput sequencing techniques, such as next-generation sequencing (NGS), has drastically reduced the cost and time required to sequence microbial genomes, making microbiome analysis more accessible and cost-effective. As sequencing technology improves, microbiome diagnostics are becoming more accurate and capable of identifying a broader range of microbial species. This has enabled the development of more comprehensive diagnostic tests that can be used in clinical settings to provide actionable insights into a patient’s health.

The growing emphasis on personalized medicine is also a significant factor propelling the market. As healthcare shifts toward individualized treatment plans based on genetic, environmental, and lifestyle factors, microbiome diagnostics are playing a key role in offering more personalized healthcare solutions. By providing a detailed analysis of a patient’s microbiome, healthcare providers can develop tailored treatment regimens that are better suited to the patient’s unique microbial profile. This approach is especially beneficial in areas such as oncology, where personalized therapies are critical for improving patient outcomes.

In addition, increasing investments in microbiome research are accelerating the development of new diagnostic tools and therapeutics. Government agencies, private companies, and research institutions are investing heavily in microbiome research to explore its potential for treating a wide range of diseases. This surge in research is leading to the discovery of new biomarkers and the development of novel diagnostic platforms, further fueling the growth of the microbiome diagnostics market. With the increasing recognition of the microbiome’s importance in human health, the market is expected to continue expanding rapidly, offering new opportunities for diagnostics companies, healthcare providers, and patients alike.

In conclusion, the microbiome diagnostics market is experiencing robust growth driven by advancements in sequencing technologies, the rise of personalized medicine, and the growing demand for precise disease management tools. As our understanding of the microbiome deepens and its role in human health becomes more recognized, microbiome diagnostics are poised to become a cornerstone of healthcare. The ability to analyze and manipulate the microbiome will not only improve disease detection but also pave the way for novel treatments and more effective prevention strategies, transforming healthcare as we know it.

SCOPE OF STUDY:

The report analyzes the Microbiome Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Microbiome Diagnostic Kits & Reagents, Microbiome Diagnostic Instruments); Technology (16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology, Other Technologies); Sample Type (Fecal Samples, Saliva Samples, Skin Samples, Other Sample Types); Application (Disease Diagnostic Application, Research Applications); End-Use (Hospitals End-Use, Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Alba Health
  • Axial Biotherapeutics
  • Beo Therapeutics
  • BioMed Technology Holdings
  • bioMerieux
  • Daye
  • Evelo Biosciences
  • Extension Health
  • Function Health
  • Microba
  • Nexilico
  • Ombre
  • Pendulum Therapeutics
  • Rebiotix Inc.
  • Seres Therapeutics
  • Siolta Therapeutics
  • Sun Genomics
  • Vedanta Biosciences
  • Viavi

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Microbiome Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Personalized Medicine Throws the Spotlight on Microbiome-Based Diagnostic Solutions
    • Growing Awareness of Gut-Brain Axis Expands Addressable Market Opportunity for Neurological Microbiome Diagnostics
    • Increasing Burden of Chronic Diseases Spurs Adoption of Microbiome Testing in Preventive Healthcare
    • Integration of Artificial Intelligence in Microbiome Analysis Accelerates Diagnostic Accuracy and Market Penetration
    • Advancements in Next-Generation Sequencing (NGS) Propel Growth of High-Resolution Microbiome Diagnostics
    • Increasing Emphasis on Holistic Health and Wellness Drives Demand for Gut Microbiome Screening Services
    • Rising Investments in Microbiome Startups Strengthens the Business Case for Commercial Diagnostic Platforms
    • Expanding Applications of Microbiome Testing in Oncology Generates New Revenue Streams and Demand
    • Government and Academic Funding Initiatives Sustain Growth Momentum for Microbiome Research and Diagnostics
    • Growing Clinical Evidence Base Validating Microbiome Biomarkers Strengthens Confidence in Diagnostic Accuracy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Microbiome Diagnostics Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Microbiome Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Microbiome Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Microbiome Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Microbiome Diagnostic Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Microbiome Diagnostic Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Microbiome Diagnostic Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Microbiome Diagnostic Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Microbiome Diagnostic Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Microbiome Diagnostic Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Sample Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Sample Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Sample Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fecal Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fecal Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Fecal Samples by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Saliva Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Saliva Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Saliva Samples by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Skin Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Skin Samples by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Skin Samples by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Disease Diagnostic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Disease Diagnostic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Disease Diagnostic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Research Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Research Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for 16S rRNA Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for 16S rRNA Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for 16S rRNA Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Shotgun Metagenomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Shotgun Metagenomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Shotgun Metagenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Metatranscriptomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Metatranscriptomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Metatranscriptomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • JAPAN
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • CHINA
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • EUROPE
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Microbiome Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Microbiome Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • FRANCE
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: France 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • GERMANY
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Germany 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Germany 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Italy 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Italy 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Italy 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Italy Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Italy 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Italy 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 173: UK Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: UK 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 176: UK Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: UK Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: UK 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 179: UK Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: UK Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: UK 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 182: UK Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: UK Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: UK 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 185: UK Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: UK 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 188: Spain Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Spain Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Spain 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 191: Spain Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Spain Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Spain 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 194: Spain Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Spain Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Spain 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Spain Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Spain 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Spain 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 203: Russia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Russia Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Russia 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 206: Russia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Russia Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Russia 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 209: Russia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Russia Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Russia 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Russia Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Russia 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Russia 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Europe Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Europe 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Rest of Europe Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Rest of Europe 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Europe Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Europe 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Europe 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 234: Asia-Pacific Historic Review for Microbiome Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Asia-Pacific Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Asia-Pacific Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 251: Australia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Australia Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Australia 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 254: Australia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Australia Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Australia 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 257: Australia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Australia Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Australia 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Australia Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Australia 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Australia 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • INDIA
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 266: India Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: India Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: India 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 269: India Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: India Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: India 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 272: India Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: India Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: India 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 275: India Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: India Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: India 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 278: India Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: India 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 281: South Korea Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: South Korea Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: South Korea 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 284: South Korea Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: South Korea Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: South Korea 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 287: South Korea Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: South Korea Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: South Korea 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: South Korea Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: South Korea 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: South Korea 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Asia-Pacific Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Asia-Pacific Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Asia-Pacific Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 311: Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 312: Latin America Historic Review for Microbiome Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Latin America 15-Year Perspective for Microbiome Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 314: Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Latin America Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 316: Latin America 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 317: Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Latin America Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 319: Latin America 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 325: Latin America 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 328: Latin America 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 329: Argentina Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Argentina Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 331: Argentina 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 332: Argentina Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Argentina Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 334: Argentina 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 335: Argentina Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Argentina Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 337: Argentina 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Argentina Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 340: Argentina 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 343: Argentina 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 344: Brazil Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Brazil Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 346: Brazil 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 347: Brazil Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Brazil Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 349: Brazil 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 350: Brazil Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Brazil Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 352: Brazil 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Brazil Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 355: Brazil 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 358: Brazil 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 359: Mexico Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Mexico Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 361: Mexico 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 362: Mexico Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Mexico Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 364: Mexico 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 365: Mexico Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Mexico Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 367: Mexico 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Mexico Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 370: Mexico 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 373: Mexico 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Latin America Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Latin America 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Latin America Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Latin America 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Latin America Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Latin America 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Latin America 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 389: Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 390: Middle East Historic Review for Microbiome Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 391: Middle East 15-Year Perspective for Microbiome Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 392: Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Middle East Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 394: Middle East 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 395: Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Middle East Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 397: Middle East 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 403: Middle East 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 406: Middle East 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 407: Iran Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Iran Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 409: Iran 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 410: Iran Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Iran Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 412: Iran 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 413: Iran Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Iran Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 415: Iran 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Iran Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 418: Iran 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 421: Iran 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 422: Israel Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Israel Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 424: Israel 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 425: Israel Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Israel Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 427: Israel 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 428: Israel Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Israel Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 430: Israel 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Israel Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 433: Israel 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 436: Israel 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Saudi Arabia Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 439: Saudi Arabia 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Saudi Arabia Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 442: Saudi Arabia 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Saudi Arabia Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 445: Saudi Arabia 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 448: Saudi Arabia 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 452: UAE Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 453: UAE Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 454: UAE 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 455: UAE Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 456: UAE Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 457: UAE 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 458: UAE Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 459: UAE Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 460: UAE 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 462: UAE Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 463: UAE 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 466: UAE 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 468: Rest of Middle East Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 469: Rest of Middle East 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 471: Rest of Middle East Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 472: Rest of Middle East 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Rest of Middle East Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 475: Rest of Middle East 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 478: Rest of Middle East 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030
  • AFRICA
    • Microbiome Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 482: Africa Recent Past, Current & Future Analysis for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Africa Historic Review for Microbiome Diagnostics by Product Type - Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 484: Africa 15-Year Perspective for Microbiome Diagnostics by Product Type - Percentage Breakdown of Value Sales for Microbiome Diagnostic Kits & Reagents and Microbiome Diagnostic Instruments for the Years 2015, 2025 & 2030
    • TABLE 485: Africa Recent Past, Current & Future Analysis for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Africa Historic Review for Microbiome Diagnostics by Sample Type - Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 487: Africa 15-Year Perspective for Microbiome Diagnostics by Sample Type - Percentage Breakdown of Value Sales for Other Sample Types, Fecal Samples, Saliva Samples and Skin Samples for the Years 2015, 2025 & 2030
    • TABLE 488: Africa Recent Past, Current & Future Analysis for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Africa Historic Review for Microbiome Diagnostics by Application - Disease Diagnostic Application and Research Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 490: Africa 15-Year Perspective for Microbiome Diagnostics by Application - Percentage Breakdown of Value Sales for Disease Diagnostic Application and Research Applications for the Years 2015, 2025 & 2030
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Africa Historic Review for Microbiome Diagnostics by End-Use - Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 493: Africa 15-Year Perspective for Microbiome Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Academic & Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2015, 2025 & 2030
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Microbiome Diagnostics by Technology - 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 496: Africa 15-Year Perspective for Microbiome Diagnostics by Technology - Percentage Breakdown of Value Sales for 16S rRNA Sequencing Technology, Shotgun Metagenomics Technology, Metatranscriptomics Technology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제